GQA Logo Quality Assurance Consulting  Global Quality Alliance vials
Home Page for GQA Consulting
Global Quality Alliance Information
Pharmaceutical Quality Consulting
GMP Training
GQA Consultants
GQA Associate Consultants
GQA Consulting Affiliates
Pharmaceutical Quality Links
GQA and Pharmaceutical Happenings
Contact GQA Quality Consultants
GMP Pharmaceutical Tanks - Validation
Laboratory Bottles
Validated cGMP Process
GQA's Associate Consultants

 
David Mayorga - GQA Associate Consultant

David Mayorga - Global Quality Alliance

David is a quality professional with 20 years of pharmaceutical and biotechnology experience with both startup and established companies.

David's industry experience has made him proficient at developing and delivering training programs, developing and executing validation protocols, conducting internal and external audits, and evaluating and implementing quality systems.

David is able to balance company goals with customer needs and safety while satisfying organizational values and applicable regulations. He is adept at communicating with a diverse work force.

Bilingual: English/Spanish


Maija Sorensen - GQA Associate Consultant

Maija Sorensen - Global Quality Alliance

Maija has over 16 years of clinical and commercial quality control, regulatory compliance and product development experience in the biotechnology industry.  Professional areas of expertise include:

  • GMP System development, implementation, auditing and gap analysis
  • Batch record review and approval
  • Analytical method development, qualification and validation
  • Specification development and justification
  • Laboratory design and start-up
  • Regulatory document review
  • Pre-licensing inspection preparation

Maija has extensive commercialization experience and is very knowledgeable regarding current regulatory requirements. She has been a significant contributor to the commercialization of the approved biotechnology products Enbrel® for rheumatoid arthritis and Vectibix® for metastatic colorectal cancer. Her clinical product experience includes monoclonal antibodies, soluble receptors, fusion proteins and small molecules.

Maija holds a B.S. degree in Molecular and Cellular Biology and Biochemistry from Western Washington University and is located in the greater Seattle area.


Marv Appleton - GQA Associate Consultant

Marv Appleton - Global Quality Alliance

In addition to his industry experience, Marv has over 22 years experience with the FDA. As an FDA investigator, Marv specialized in cGMP, Quality System Regulation, and PMA inspections of domestic and foreign medical device manufacturers. He routinely conducted PAI and cGMP inspections of pharmaceutical manufacturers.

From an industry perspective, Marv was a Corporate Compliance and QA auditor at Amgen in Thousand Oaks, California for five years. He performed internal audits at Amgen facilities worldwide and audits of contract manufacturers and suppliers.

Marv has created and presented numerous training classes throughout his career.


Amy Taylor - GQA Associate Consultant

Amy taylor - Regulatory Affairs and Quality Consulting 

Ms. Taylor has over twenty-three years of healthcare industry experience in regulatory affairs, product development, quality control, quality assurance, and manufacturing disciplines with an in-depth knowledge of product development requirements for pharmaceuticals, medical devices, and combination products.










 


Validation

Establishing documented
evidence that provides a
high degree of assurance
that a system, method, or
operation does what it is
supposed to do, reliably
and consistently.


Qualification

The action of proving
that any equipment or
process works correctly
and consistently and
produces the expected
results. Qualification is
a part of, but not limited
to, a validation process,
i.e.: installation
qualification (IQ),
operational qualification
(OQ), and performance
qualification (PQ).



21 CFR Part 11

Title 21 CFR Part 11 of the
Code of Federal Regulations
deals with the FDA guidelines
on electronic records and
electronic signatures. Part 11,
as it is commonly called,
defines the criteria under
which electronic records and
electronic signatures are
considered to be trustworthy,
reliable and equivalent to
paper records.

Practically speaking, Part 11
requires drug makers,
medical device manufacturers,
biotech companies, biologics
developers, and other
FDA-regulated industries to
implement controls,
including audits, system
validations, audit trails,
electronic signatures, and
documentation for software
and systems involved in
processing many forms of data
as part of business operations
and product development.

The rule also applies to
submissions made to the FDA
in electronic format
(i.e. a New Drug Application)
but not to paper submissions
by electronic methods
(i.e. faxes).

Home  |  About Us  |  Our Services  |  Training  |  Meet the GQA Team  |  GQA Associate Consultants  |  GQA Affiliates  |  Industry Links  |  What's New  |  Contact Us

© 2007, 2008 by Global Quality Alliance, LLC. /  All rights reserved. | Revised 06/08